268 related articles for article (PubMed ID: 37916971)
1. Translational Aspects of Epithelioid Sarcoma: Current Consensus.
Grünewald TGP; Postel-Vinay S; Nakayama RT; Berlow NE; Bolzicco A; Cerullo V; Dermawan JK; Frezza AM; Italiano A; Jin JX; Le Loarer F; Martin-Broto J; Pecora A; Perez-Martinez A; Tam YB; Tirode F; Trama A; Pasquali S; Vescia M; Wortmann L; Wortmann M; Yoshida A; Webb K; Huang PH; Keller C; Antonescu CR
Clin Cancer Res; 2024 Mar; 30(6):1079-1092. PubMed ID: 37916971
[TBL] [Abstract][Full Text] [Related]
2. Infrequent SMARCB1/INI1 gene alteration in epithelioid sarcoma: a useful tool in distinguishing epithelioid sarcoma from malignant rhabdoid tumor.
Kohashi K; Izumi T; Oda Y; Yamamoto H; Tamiya S; Taguchi T; Iwamoto Y; Hasegawa T; Tsuneyoshi M
Hum Pathol; 2009 Mar; 40(3):349-55. PubMed ID: 18973917
[TBL] [Abstract][Full Text] [Related]
3. Consistent SMARCB1 homozygous deletions in epithelioid sarcoma and in a subset of myoepithelial carcinomas can be reliably detected by FISH in archival material.
Le Loarer F; Zhang L; Fletcher CD; Ribeiro A; Singer S; Italiano A; Neuville A; Houlier A; Chibon F; Coindre JM; Antonescu CR
Genes Chromosomes Cancer; 2014 Jun; 53(6):475-86. PubMed ID: 24585572
[TBL] [Abstract][Full Text] [Related]
4. Beyond SMARCB1 Loss: Recent Insights into the Pathobiology of Epithelioid Sarcoma.
Del Savio E; Maestro R
Cells; 2022 Aug; 11(17):. PubMed ID: 36078034
[TBL] [Abstract][Full Text] [Related]
5. SWI/SNF Chromatin-remodeling Complex Status in SMARCB1/INI1-preserved Epithelioid Sarcoma.
Kohashi K; Yamamoto H; Yamada Y; Kinoshita I; Taguchi T; Iwamoto Y; Oda Y
Am J Surg Pathol; 2018 Mar; 42(3):312-318. PubMed ID: 29309303
[TBL] [Abstract][Full Text] [Related]
6. SMARCB1 protein and mRNA loss is not caused by promoter and histone hypermethylation in epithelioid sarcoma.
Papp G; Changchien YC; Péterfia B; Pecsenka L; Krausz T; Stricker TP; Khoor A; Donner L; Sápi Z
Mod Pathol; 2013 Mar; 26(3):393-403. PubMed ID: 23174932
[TBL] [Abstract][Full Text] [Related]
7. SMARCB1/INI1 tumor suppressor gene is frequently inactivated in epithelioid sarcomas.
Modena P; Lualdi E; Facchinetti F; Galli L; Teixeira MR; Pilotti S; Sozzi G
Cancer Res; 2005 May; 65(10):4012-9. PubMed ID: 15899790
[TBL] [Abstract][Full Text] [Related]
8. Re: Infrequent SMARCB1/INI1 gene alteration in epithelioid sarcoma: a useful tool in distinguishing epithelioid sarcoma from malignant rhabdoid tumor: Direct evidence of mutational inactivation of SMARCB1/INI1 in epithelioid sarcoma.
Flucke U; Slootweg PJ; Mentzel T; Pauwels P; Hulsebos TJ
Hum Pathol; 2009 Sep; 40(9):1361-2; author reply 1362-4. PubMed ID: 19683621
[No Abstract] [Full Text] [Related]
9. Functional genomic analysis of epithelioid sarcoma reveals distinct proximal and distal subtype biology.
Rasmussen SV; Jin JX; Bickford LR; Woods AD; Sahm F; Crawford KA; Nagamori K; Goto H; Torres KE; Sidoni A; Rudzinski ER; Thway K; Jones RL; Ciulli A; Wright H; Lathara M; Srinivasa G; Kannan K; Huang PH; Grünewald TGP; Berlow NE; Keller C
Clin Transl Med; 2022 Jul; 12(7):e961. PubMed ID: 35839307
[TBL] [Abstract][Full Text] [Related]
10. SMARCB1/INI1 genetic inactivation is responsible for tumorigenic properties of epithelioid sarcoma cell line VAESBJ.
Brenca M; Rossi S; Lorenzetto E; Piccinin E; Piccinin S; Rossi FM; Giuliano A; Dei Tos AP; Maestro R; Modena P
Mol Cancer Ther; 2013 Jun; 12(6):1060-72. PubMed ID: 23576573
[TBL] [Abstract][Full Text] [Related]
11. Epithelioid sarcoma is associated with a high percentage of SMARCB1 deletions.
Sullivan LM; Folpe AL; Pawel BR; Judkins AR; Biegel JA
Mod Pathol; 2013 Mar; 26(3):385-92. PubMed ID: 23060122
[TBL] [Abstract][Full Text] [Related]
12. Tazemetostat in advanced epithelioid sarcoma with loss of INI1/SMARCB1: an international, open-label, phase 2 basket study.
Gounder M; Schöffski P; Jones RL; Agulnik M; Cote GM; Villalobos VM; Attia S; Chugh R; Chen TW; Jahan T; Loggers ET; Gupta A; Italiano A; Demetri GD; Ratan R; Davis LE; Mir O; Dileo P; Van Tine BA; Pressey JG; Lingaraj T; Rajarethinam A; Sierra L; Agarwal S; Stacchiotti S
Lancet Oncol; 2020 Nov; 21(11):1423-1432. PubMed ID: 33035459
[TBL] [Abstract][Full Text] [Related]
13. Claudin-4 expression distinguishes SWI/SNF complex-deficient undifferentiated carcinomas from sarcomas.
Schaefer IM; Agaimy A; Fletcher CD; Hornick JL
Mod Pathol; 2017 Apr; 30(4):539-548. PubMed ID: 28084340
[TBL] [Abstract][Full Text] [Related]
14. [Molecular genetics and immunophenotype of INI1/SMARCB in epithelioid sarcoma].
Li L; Xia Q; Rao Q; Liu B; Wu B; Shi S; Yu B; Zhang R; Lu Z; Zhou X
Zhonghua Bing Li Xue Za Zhi; 2014 Jun; 43(6):389-93. PubMed ID: 25208989
[TBL] [Abstract][Full Text] [Related]
15. Targeting epigenetics in sarcomas through EZH2 inhibition.
Italiano A
J Hematol Oncol; 2020 Apr; 13(1):33. PubMed ID: 32264965
[TBL] [Abstract][Full Text] [Related]
16. Differential microRNA expression profiles between malignant rhabdoid tumor and epithelioid sarcoma: miR193a-5p is suggested to downregulate SMARCB1 mRNA expression.
Kohashi K; Yamamoto H; Kumagai R; Yamada Y; Hotokebuchi Y; Taguchi T; Iwamoto Y; Oda Y
Mod Pathol; 2014 Jun; 27(6):832-9. PubMed ID: 24287458
[TBL] [Abstract][Full Text] [Related]
17. Intra-articular epithelioid sarcoma showing mixed classic and proximal-type features: report of 2 cases, with immunohistochemical and molecular cytogenetic INI-1 study.
Kosemehmetoglu K; Kaygusuz G; Bahrami A; Raimondi SC; Kilicarslan K; Yildiz Y; Folpe AL
Am J Surg Pathol; 2011 Jun; 35(6):891-7. PubMed ID: 21566521
[TBL] [Abstract][Full Text] [Related]
18. SMARCB1-deficient Vulvar Neoplasms: A Clinicopathologic, Immunohistochemical, and Molecular Genetic Study of 14 Cases.
Folpe AL; Schoolmeester JK; McCluggage WG; Sullivan LM; Castagna K; Ahrens WA; Oliva E; Biegel JA; Nielsen GP
Am J Surg Pathol; 2015 Jun; 39(6):836-49. PubMed ID: 25651469
[TBL] [Abstract][Full Text] [Related]
19. SWI/SNF complex-deficient soft tissue neoplasms: An update.
Schaefer IM; Hornick JL
Semin Diagn Pathol; 2021 May; 38(3):222-231. PubMed ID: 32646614
[TBL] [Abstract][Full Text] [Related]
20. p53 Pathway Inactivation Drives SMARCB1-deficient p53-wildtype Epithelioid Sarcoma Onset Indicating Therapeutic Vulnerability Through MDM2 Inhibition.
Oppel F; Shao S; Gendreizig S; Zimmerman MW; Schürmann M; Flavian VF; Goon P; Chi SN; Aster JC; Sudhoff H; Look AT
Mol Cancer Ther; 2022 Nov; 21(11):1689-1700. PubMed ID: 36099437
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
